Spinal cord stimulation
Ask the expert
The report presents a summary of the reimbursement situation for use of spinal cord stimulation. Indications include neuropathic and ischemic pain.
Clinical scenarios include trial insertion of electrodes and external stimulator, permanent implantation of spinal cord stimulator, adjustment/programming of stimulator, removal of stimulator, and replacement of battery of pulse generation.
The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
- The Netherlands
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of the spinal cord stimulation devices include:
- Boston Scientific (Precision)
- Nevro (Senza)
- Stimwave (Freedom SCS)
- Abbot Vascular (BurstDR: Proclaim, Prodigy MRI IPG, St. Jude Medical Invisible Trial System; Eon)
- Medtronic (Intellis; SureScan: RestoreSenso, RestoreUltra, RestoreAdvanced, PrimeAdvanced)
- Saluda Medical (Evoke SCS System)
- Nuvectra (Algovita SCS)
- Med-Ally (VersaStim IPG Platform)
Table of content is not available at this moment.
On January 14, 2022, the Government of the Russian Federation released a Decree which approved the inclusion of three devices (implantable pulse generator for urinary/fecal incontinence, bioprosthetic aortic valve/xenoprosthesis, and vessels embolization material) in the List of Essential Implantable Medical Devices.Read more
In December 2021, the National Institute for Health Research (NIHR) in England released two MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned improving continence in children and young people with neurodisability, and augmented trabeculectomy in glaucoma. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.Read more
The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in October 2021. More than 20 recommendations were published in relation to the registration, modification of registration conditions, renewal of registration of devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, peripheral vascular, neurovascular and neuromodulation, and other groups of devices, as well as medical aids.Read more
In late September 2021, the Austrian version of the DRG system (LKF) 2022 model with the relevant supplementary documents was published in Austria. The document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, E-Health, and gastrointestinal area.Read more
In late September 2021, the Danish Health Data Agency (Sundhedsstyrelsen) has published the update of the Health Care Classification System (Sundheds-væsenets Klassifikations System, SKS). The most significant changes include: 31 new diagnosis codes and 14 procedure codes were added. The newly added procedure codes concern mainly pulmonary and airways area and neuromodulation procedures.Read more